Related Experiment Video
Updated: Aug 16, 2026

Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: July 1, 2013
The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome
1Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Royal Perth Hospital, Wellington Street, Perth, 6000, Western Australia.
Abstract:
Fat redistribution associated with the use of antiretroviral therapy, which has been broadly termed 'lipodystrophy', incorporates distinct body composition changes including lipoatrophy (subcutaneous fat loss) as well as fat accumulation. This review examines the role of nucleoside reverse transcriptase inhibitor (NRTI) therapy in the overall context of lipodystrophy, providing converging evidence from observational cohort studies, clinical trials and pathological studies that lipoatrophy is strongly and specifically associated with the use of certain NRTI drugs (stavudine more than zidovudine), and that host factors also have a modulating effect on risk of NRTI-associated lipoatrophy. Implications for clinical assessment and management are also considered, within a broader contest that incorporates treatment efficacy as well as toxicity.
Related Concept Videos
Retrovirus Life Cycles
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors

